

Patients randomized
(n = 61)

Not treated
(n = 1)

Trilaciclib 240 mg/m² prior to
topotecan 1.5 mg/m²
(n = 32)

Placebo prior to
topotecan 1.5 mg/m²
(n = 29)

Study drug disposition

Ongoing (n = 1)

Discontinued (n = 31)

- Disease progression (n = 24)
- Withdrawal of consent by patient (n = 2)
- Withdrawal of consent by investigator (n = 1)
- Adverse event (n = 4)

Study drug disposition

Ongoing (n = 0)

Discontinued (n = 28)

- Disease progression (n = 13)
- Withdrawal of consent by patient (n = 5)
- Withdrawal of consent by investigator (n = 1)
- Adverse event (n = 7)
- Other (n = 2)

Study drug disposition

Ongoing (n = 1)

Discontinued (n = 31)

- Withdrawal of consent by patient (n = 1)
- Death (n = 29)
 - Lung cancer (n = 28)
 - Cerebrovascular insult/event (n = 1)
- Other (n = 1)

Study drug disposition

Ongoing (n = 0)

Discontinued (n = 29)

- Withdrawal of consent by patient (n = 3)
- Death (n = 24)
 - Lung cancer (n = 23)
 - Septicemia (n = 1)
- Lost to follow-up (n = 1)
- Other (n = 1)